logo
Share SHARE
FONT-SIZE Plus   Neg

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Courier Corp. (CRRC) announced Wednesday that its Board has reasonably determined that the non-binding, unsolicited proposal from R.R. Donnelley & Sons Company (RRD) to acquire the Company for $23.00 per share in cash or RR Donnelley common stock is reasonably likely to result in a "Superior Proposal"... Diversified electronics maker TE Connectivity Ltd. agreed Wednesday to sell its broadband network solutions or BNS business unit to telecommunications company CommScope Holding Co., Inc. in an all-cash deal valued at about $3 billion. The sale will enable TE to focus on providing leading connectivity and sensor solutions, particularly harsh environment connectivity. Online foreign exchange trading company FXCM Inc (FXCM) on Wednesday announced its decision to forgive about 90% of its clients who incurred negative balances in certain jurisdictions, on January 15 as a result of the Swiss National Bank announcement on that date. FXCM will notify the applicable clients...
comments powered by Disqus
Follow RTT